Skip to main content

Exploiting novel biology to gain revolutionary power over cancer

Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug ConjugatesTM (ND-ADCs) to address the hallmarks of cancer lethality

Vision:

No one should die of cancer

Mission:

Exploiting novel biology to gain revolutionary power over cancer.

Our Science

Our novel and first-in-class Nuclear-Delivered Antibody-Drug ConjugatesTM (ND-ADCs) target an intracellular transporter called TM4SF1. TM4SF1 is highly expressed in the tumor microenvironment and carries proteins – and our antibodies – from the cell surface to the nucleus.

TM4SF1 has high expression across all solid tumors with a correlation to mortality. Expression is in both tumor cells and tumor vascular endothelium. Selective delivery to these cells may result in high therapeutic margin with little delivery to health tissue

Exploiting the biology of TM4SF1 and the nuclear delivery of payloads may unlock exceptional efficacy through novel and potent mechanisms of action:

  • Antiangiogenesis (regression of angiogenic tumor vasculature)
  • Tumor cell killing (especially invasive and metastic tumor cells)
  • Immune activation

Angiex’s lead drug AGX101 is now entering the clinic, and the company is actively pursuing a pipeline of future ND-ADCs.

Our Values:

DRIVEN BY SCIENCE

Curious with a purpose, truthful, committed to accuracy and reproducibility

CREATIVE AND COURAGEOUS

Innovative, thoughtful, gritty, aiming high but rolling up our sleeves and tending to detail

CONTRIBUTORS WITHOUT EGO

Resourceful, flexible, self aware, generous to others, comfortable both as teacher and student

RESPECTFUL AND INCLUSIVE

Team oriented, cooperative, communicative, and present for one another

FOR LIFE, FOR ALL

Motivated to save lives, driven to bring good to patients, shareholders, and coworkers

Leadership Team

Chief Executive Officer

Marty J. Duvall

Marty J. Duvall is an experienced oncology leader with 30+ years of pharmaceutical drug development experience. Prior to Angiex, he was CEO of Tocagen and Oncopeptides; Chief Commercial Officer at ARIAD Pharmaceuticals (now Takeda); Oncology Therapeutic Franchise Head at Merck; Head of Commercial at MGI Pharma (now Eisai) and Abraxis Bioscience (now Celgene); Global Head of Taxotere Medical and Marketing at Aventis (now Sanofi).
Founder, President and COO

Paul Jaminet, Ph.D.

Paul Jaminet, Ph.D., is founder, president, and COO at Angiex. Paul began his career as an Astrophysicist at the Harvard-Smithsonian Center for Astrophysics before becoming a software entrepreneur during the Internet boom of the 1990s. Paul has 20 years of experience as an entrepreneur-executive in health and technology businesses. Immediately prior to Angiex he founded the Perfect Health Retreat (2013-present) and PerfectHealthDiet.com (2010-present), and wrote the book Perfect Health Diet (Scribner, 2012). He holds a Ph.D. in physics from the University of California at Berkeley and B.S. degrees in physics and philosophy from the Massachusetts Institute of Technology.
Chief Medical Officer

Jason Sager, MD

Following a 12-year career as a practicing pediatric oncologist, Dr. Sager gained extensive oncology drug development experience at Genentech, Novartis, Sanofi and Ikena Oncology where he led the early clinical development of many important therapeutics. His résumé includes 14 INDs. Over the past 18 months, he led the design of the clinical program for Angiex’s lead drug, AGX101.
Founder, VP of Discovery Science

Shou-Ching Jaminet, Ph.D.

Shou-Ching Jaminet, Ph.D., is founder and VP of Discovery Science at Angiex. Shou-Ching is a molecular and vascular biologist, a leading expert on gene expression profiling and TM4SF1 biology, and discoverer of TM4SF1’s roles in endothelial cell biology. Before coming to Angiex, she was Director of the Laboratory of Multi-Gene Transcriptional Profiling at Beth Israel Deaconess Medical Center, and member of faculty at Harvard Medical School. She is co-author of Perfect Health Diet (Scribner, 2012).
Founder, Chair of Scientific Advisory Board

Dr. Harold (Hal) Dvorak, M.D.

Harold (Hal) Dvorak, M.D., is founder and chair of the scientific advisory board at Angiex, and Mallinckrodt Distinguished Professor of Pathology Emeritus at Harvard Medical School. Hal is best known as the discoverer of VEGF-A and is a leading expert on tumor vessel structures. He was Chief of the Department of Pathology at Beth Israel Deaconess Medical Center from 1979 to 2005, Director of the Center for Vascular Biology Research at BIDMC from 2003 to 2010, and is currently Director at the BIDMC Cancer Center. He is a recipient of the Gairdner International Award (2014) and numerous other prizes and honors.
Project Team Lead

Steve Slocum, Ph.D.

Stephen Slocum has been with Angiex since 2018 and is the Project Team Lead for AGX101. Prior to joining Angiex, he earned his PhD in Biochemistry and Molecular Biology at the Johns Hopkins University, and completed a post doc at MIT alongside serving as a director for the Center for Environmental Health Sciences Bioanalytical Facilities Core.

Board of Directors

Executive Chairman

Iain Dukes, D.Phil.

Iain Dukes is executive chairman of Angiex, and venture partner at Orbimed Advisors. He has served as CEO or chairman of numerous biotherapeutics companies including Theseus Pharmaceuticals, Iovance, KaNDY Therapeutics, Viriom. Before joining Orbimed, Iain was SVP BD & Licensing at Merck; before Merck Iain was VP External R&D at Amgen.
Chief Executive Officer

Marty J. Duvall

Marty J. Duvall is an experienced oncology leader with 30+ years of pharmaceutical drug development experience. Prior to Angiex, he was CEO of Tocagen and Oncopeptides; Chief Commercial Officer at ARIAD Pharmaceuticals (now Takeda); Oncology Therapeutic Franchise Head at Merck; Head of Commercial at MGI Pharma (now Eisai) and Abraxis Bioscience (now Celgene); Global Head of Taxotere Medical and Marketing at Aventis (now Sanofi).
Founder, President and COO

Paul Jaminet, Ph.D.

Paul Jaminet, Ph.D., is founder, president, and COO at Angiex. Paul began his career as an Astrophysicist at the Harvard-Smithsonian Center for Astrophysics before becoming a software entrepreneur during the Internet boom of the 1990s. Paul has 20 years of experience as an entrepreneur-executive in health and technology businesses. Immediately prior to Angiex he founded the Perfect Health Retreat (2013-present) and PerfectHealthDiet.com (2010-present), and wrote the book Perfect Health Diet (Scribner, 2012). He holds a Ph.D. in physics from the University of California at Berkeley and B.S. degrees in physics and philosophy from the Massachusetts Institute of Technology.

Errik Anderson

Jason Camm

Thiel Capital

Fabian Hansen

Presight Capital

Karen Chu

Fontus Capital